Latest revision as of 17:45, 23 June 2024

Back to Top

Section editor
	TBA

10 regimens on this page 13 variants on this page

Note: this page has regimens which are specific to breast cancer that is BRCA-mutated. Please see the main breast cancer page for other chemotherapy regimens.

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO

2024: Bedrosian et al. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline PubMed
2021: Tung et al. Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update PubMed
2020: Tung et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline PubMed

ESMO

2011: Balmaña et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines PubMed

NCCN

NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Breast Cancer.

Adjuvant therapy

Olaparib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Tutt et al. 2021 (OlympiA)	2014-2019	Phase 3 (E-RT-esc)	Placebo	Superior iDFS (primary endpoint) iDFS36: 85.9% vs 77.1% (HR 0.58, 99.5% CI 0.41-0.82) Superior OS¹ (secondary endpoint) OS48: 89.8% vs 86.4% (HR 0.68, 98.5% CI 0.47-0.97)

¹Reported efficacy is based on the 2022 update.

Preceding treatment

Primary local treatment +/- (neo-)adjuvant therapy

Targeted therapy

Olaparib (Lynparza) 300 mg PO twice per day

28-day cycle for 13 cycles (1 year)

References

OlympiA: Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405. Epub 2021 Jun 3. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02032823
1. Update: Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec 1;33(12):1250-1268. Epub 2022 Oct 10. link to original article PubMed
2. PRO analysis: Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. Epub 2024 Feb 1. link to original article PubMed

Advanced or metastatic disease, subsequent lines of therapy

Capecitabine monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Litton et al. 2018 (EMBRACA)	2013-10 to 2017-04	Phase 3 (C)	Talazoparib	Inferior PFS
Robson et al. 2017 (OlympiAD)	2014-04-07 to 2015-11-27	Phase 3 (C)	Olaparib	Inferior PFS

Biomarker eligibility criteria

EMBRACA: Germline BRCA1 or BRCA2 mutation
OlympiAD: Confirmed deleterious or suspected deleterious germline BRCA mutation

Chemotherapy

Capecitabine (Xeloda) 1250 mg/m² PO twice per day on days 1 to 14

21-day cycles

References

OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains dosing details in manuscript PubMed NCT02000622
1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains dosing details in supplement PubMed NCT01945775
1. PRO analysis: Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. link to original article PubMed
2. Update: Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. link to original article PubMed

Carboplatin monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Tutt et al. 2018 (TNT)	2008-2014	Phase 3 (E-switch-ic)	Docetaxel	Superior ORR¹ (primary endpoint)

¹Reported efficacy is based on subgroup analysis.

Chemotherapy

Carboplatin (Paraplatin) AUC 6 IV once on day 1

21-day cycle for 6 to 8 cycles

References

TNT: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00532727

Carboplatin & Paclitaxel (CP)

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Diéras et al. 2020 (BROCADE3)	2014-2018	Phase 3 (C)	CP & Veliparib	Inferior PFS (primary endpoint) Did not meet secondary endpoint of OS¹

¹Reported efficacy is based on the 2024 update.

Biomarker eligibility criteria

Confirmed deleterious germline BRCA1 or BRCA2 mutation

Chemotherapy

Carboplatin (Paraplatin) AUC 6 IV once on day 1
Paclitaxel (Taxol) 80 mg/m² IV once per day on days 1, 8, 15

21-day cycles

References

BROCADE3: Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269-1282. Epub 2020 Aug 27. link to original article contains dosing details in manuscript PubMed NCT02163694
1. Update: Diéras V, Han HS, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Loirat D, Ratajczak C, Adamu H, Girardi V, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar;200:113580. Epub 2024 Jan 28. link to original article PubMed

Docetaxel monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Tutt et al. 2018 (TNT)	2008-2014	Phase 3 (C)	Carboplatin	Inferior ORR¹

¹Reported efficacy is based on subgroup analysis.

Chemotherapy

Docetaxel (Taxotere) 100 mg/m² IV once on day 1

21-day cycle for 6 to 8 cycles

References

TNT: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00532727

Eribulin monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Litton et al. 2018 (EMBRACA)	2013-10 to 2017-04	Phase 3 (C)	Talazoparib	Inferior PFS
Robson et al. 2017 (OlympiAD)	2014-04-07 to 2015-11-27	Phase 3 (C)	Olaparib	Inferior PFS

Biomarker eligibility criteria

EMBRACA: Germline BRCA1 or BRCA2 mutation
OlympiAD: Confirmed deleterious or suspected deleterious germline BRCA mutation

Chemotherapy

Eribulin (Halaven) 1.4 mg/m² IV over 2 to 5 minutes once per day on days 1 & 8

21-day cycles

References

OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains dosing details in manuscript PubMed NCT02000622
1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains dosing details in supplement PubMed NCT01945775
1. PRO analysis: Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. link to original article PubMed
2. Update: Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. link to original article PubMed

Gemcitabine monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Litton et al. 2018 (EMBRACA)	2013-10 to 2017-04	Phase 3 (C)	Talazoparib	Inferior PFS

Biomarker eligibility criteria

Germline BRCA1 or BRCA2 mutation

Chemotherapy

Gemcitabine (Gemzar) 1250 mg/m² IV over 30 minutes once per day on days 1 & 8

21-day cycles

References

EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains dosing details in supplement PubMed NCT01945775
1. PRO analysis: Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. link to original article PubMed
2. Update: Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. link to original article PubMed

Olaparib monotherapy

Regimen variant #1, 100 mg twice per day

Study	Dates of enrollment	Evidence
Tutt et al. 2010 (KU36-44)	2007-2008	Phase 2

Targeted therapy

Olaparib (Lynparza) 100 mg PO twice per day

Continued indefinitely

Regimen variant #2, 300 mg twice per day

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Robson et al. 2017 (OlympiAD)	2014-04-07 to 2015-11-27	Phase 3 (E-RT-switch-ooc)	Investigator's choice of: 1a. Capecitabine 1b. Eribulin 1c. Vinorelbine	Superior PFS (primary endpoint) Median PFS: 7.0 vs 4.2 mo (HR 0.58, 95% CI 0.43-0.80) Did not meet secondary endpoint of OS¹ Median OS: 19.3 vs 17.1 mo (HR 0.90, 95% CI 0.66-1.23)

¹Reported efficacy for OS is based on the 2019 update.

Biomarker eligibility criteria

Confirmed deleterious or suspected deleterious germline BRCA mutation

Targeted therapy

Olaparib (Lynparza) 300 mg PO twice per day

Continued indefinitely

Regimen variant #3, 400 mg twice per day

Study	Dates of enrollment	Evidence
Tutt et al. 2010 (KU36-44)	2007-2008	Phase 2
Kaufman et al. 2014 (Study 42)	2010-02-21 to 2012-07-31	Phase 2

Biomarker eligibility criteria

Study 42: Germline BRCA1/2 mutations

Prior treatment criteria

Study 42: Progression after at least three lines of treatment for metastatic disease.

Targeted therapy

Olaparib (Lynparza) 400 mg PO twice per day

Continued indefinitely

References

KU36-44: Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. link to original article PubMed NCT00494234
Study 42: Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01078662
OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains dosing details in manuscript PubMed NCT02000622
1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed

Talazoparib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Turner et al. 2018 (ABRAZO)	2014-05 to 2016-02	Phase 2
Litton et al. 2018 (EMBRACA)	2013-10 to 2017-04	Phase 3 (E-RT-switch-ooc)	Physician's choice of: 1a. Capecitabine 1b. Eribulin 1c. Gemcitabine 1d. Vinorelbine	Superior PFS (primary endpoint) Median PFS: 8.6 vs 5.6 mo (HR 0.54, 95% CI 0.41-0.71) Did not meet secondary endpoint of OS¹ Median OS: 19.3 vs 19.5 mo (HR 0.85, 95% CI 0.67-1.07)

¹Reported efficacy for OS is based on the 2020 update.

Biomarker eligibility criteria

Germline BRCA1 or BRCA2 mutation

Targeted therapy

Talazoparib (Talzenna) 1 mg PO once per day

Continued indefinitely

References

ABRAZO: Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 May 1;25(9):2717-2724. Epub 2018 Dec 18. link to original article contains dosing details in abstract PubMed NCT02034916
EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains dosing details in abstract PubMed NCT01945775
1. PRO analysis: Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. link to original article PubMed
2. Update: Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. link to original article PubMed

Vinorelbine monotherapy

Regimen variant #1, 2 out of 3 weeks

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Robson et al. 2017 (OlympiAD)	2014-04-07 to 2015-11-27	Phase 3 (C)	Olaparib	Inferior PFS

Biomarker eligibility criteria

Confirmed deleterious or suspected deleterious germline BRCA mutation

Chemotherapy

Vinorelbine (Navelbine) 30 mg/m² IV once per day on days 1 & 8

21-day cycles

Regimen variant #2, weekly

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Litton et al. 2018 (EMBRACA)	2013-10 to 2017-04	Phase 3 (C)	Talazoparib	Inferior PFS

Biomarker eligibility criteria

Germline BRCA1 or BRCA2 mutation

Chemotherapy

Vinorelbine (Navelbine) 30 mg/m² IV over 6 to 10 minutes once per day on days 1, 8, 15

21-day cycles

References

OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains dosing details in manuscript PubMed NCT02000622
1. Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains dosing details in supplement PubMed NCT01945775
1. PRO analysis: Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. link to original article PubMed
2. Update: Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. link to original article PubMed

Additional resources

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-{{#lst:Section editor transclusions|breast}}
+{{#lst:Editorial board transclusions|breast}}
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 12: / Line 12: @@
 {{TOC limit|limit=3}}
 =Guidelines=
+'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 ==[http://www.asc.org/ ASCO]==
-*'''2021:''' Tung et al. [https://doi.org/10.1200/jco.21.01532 Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update]
+*'''2024:''' Bedrosian et al. [https://doi.org/10.1200/jco.23.02225 Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline] [https://pubmed.ncbi.nlm.nih.gov/38175972/ PubMed]
+*'''2021:''' Tung et al. [https://doi.org/10.1200/jco.21.01532 Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update] [https://pubmed.ncbi.nlm.nih.gov/34343058/ PubMed]
+*'''2020:''' Tung et al. [https://doi.org/10.1200/jco.20.00299 Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline] [https://pubmed.ncbi.nlm.nih.gov/32243226/ PubMed]
-==[http://www.esmo.org/ ESMO]==
+==[https://www.esmo.org/ ESMO]==
-*'''2011:''' Balmaña et al. [https://doi.org/10.1093/annonc/mdr373 BRCA in breast cancer: ESMO Clinical Practice Guidelines]
+*'''2011:''' Balmaña et al. [https://doi.org/10.1093/annonc/mdr373 BRCA in breast cancer: ESMO Clinical Practice Guidelines] [https://pubmed.ncbi.nlm.nih.gov/21908500/ PubMed]
+==NCCN==
+*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419 NCCN Guidelines - Breast Cancer].''
 =Adjuvant therapy=
 ==Olaparib monotherapy {{#subobject:56hxcd|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:3b0yga|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 28: / Line 33: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
-|[https://doi.org/10.1056/nejmoa2105215 Tutt et al. 2021 (OlympiA)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9126186/ Tutt et al. 2021 (OlympiA)]
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-331-1 <span style="color:white;">ESMO-MCBS (A)</span>]'''
+|-
+|} -->
 |2014-2019
 | style="background-color:#1a9851" |Phase 3 (E-RT-esc)
 |[[Breast_cancer_-_null_regimens#Placebo|Placebo]]
-|style="background-color:#1a9850"|Superior invasive DFS<br>IDFS36: 86% vs 77%<br>(HR 0.58, 99.5% CI 0.41-0.82)
+| style="background-color:#1a9850" |Superior iDFS (primary endpoint)<br>iDFS36: 85.9% vs 77.1%<br>(HR 0.58, 99.5% CI 0.41-0.82)<br><br>Superior OS<sup>1</sup> (secondary endpoint)<br>OS48: 89.8% vs 86.4%<br>(HR 0.68, 98.5% CI 0.47-0.97)
 |-
 |}
+''<sup>1</sup>Reported efficacy is based on the 2022 update.''
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Surgery#Breast_cancer_surgery|Primary local treatment]] +/- (neo-)adjuvant therapy
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Olaparib (Lynparza)]] 300 mg PO twice per day
 '''28-day cycle for 13 cycles (1 year)'''
+</div></div>
 ===References===
-# '''OlympiA:''' Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405. Epub 2021 Jun 3. [https://doi.org/10.1056/nejmoa2105215 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34081848/ PubMed] NCT02032823
+# '''OlympiA:''' Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405. Epub 2021 Jun 3. [https://doi.org/10.1056/nejmoa2105215 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9126186/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34081848/ PubMed] [https://clinicaltrials.gov/study/NCT02032823 NCT02032823]
+##'''Update:''' Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec 1;33(12):1250-1268. Epub 2022 Oct 10. [https://doi.org/10.1016/j.annonc.2022.09.159 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36228963/ PubMed]
+##'''PRO analysis:''' Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. Epub 2024 Feb 1. [https://doi.org/10.1200/jco.23.01214 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38301187/ PubMed]
 =Advanced or metastatic disease, subsequent lines of therapy=
 ==Capecitabine monotherapy {{#subobject:842c42|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:fb2810|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 63: / Line 76: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
-|2013-2017
+|2013-10 to 2017-04
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Talazoparib_monotherapy|Talazoparib]]
@@ Line 69: / Line 82: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
-|2014-2015
+|2014-04-07 to 2015-11-27
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Olaparib_monotherapy_2|Olaparib]]
@@ Line 75: / Line 88: @@
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *EMBRACA: Germline BRCA1 or BRCA2 mutation
 *OlympiAD: Confirmed deleterious or suspected deleterious germline BRCA mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] NCT02000622
+# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601/ PubMed] [https://clinicaltrials.gov/study/NCT02000622 NCT02000622]
-## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed]
+## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707/ PubMed]
-# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] NCT01945775
+# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579/ PubMed] [https://clinicaltrials.gov/study/NCT01945775 NCT01945775]
-## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825 PubMed]
+##'''PRO analysis:''' Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. [https://doi.org/10.1093/annonc/mdy257 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30124753/ PubMed]
+## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825/ PubMed]
 ==Carboplatin monotherapy {{#subobject:16h4a8|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:ujsx06|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 103: / Line 118: @@
 |style="background-color:#1a9851"|Phase 3 (E-switch-ic)
 |[[#Docetaxel_monotherapy|Docetaxel]]
-| style="background-color:#1a9850" |Superior ORR<sup>1</sup>
+| style="background-color:#1a9850" |Superior ORR<sup>1</sup> (primary endpoint)
 |-
 |}
 ''<sup>1</sup>Reported efficacy is based on subgroup analysis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
 '''21-day cycle for 6 to 8 cycles'''
+</div></div>
 ===References===
-# '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://www.nature.com/articles/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29713086 PubMed] NCT00532727
+# '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://doi.org/10.1038/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29713086/ PubMed] [https://clinicaltrials.gov/study/NCT00532727 NCT00532727]
 ==Carboplatin & Paclitaxel (CP) {{#subobject:842252|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:f16cn0|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 128: / Line 142: @@
 |2014-2018
 | style="background-color:#1a9851" |Phase 3 (C)
-|[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_Veliparib_88|CP & Veliparib]]
+|[[#Carboplatin_.26_Paclitaxel_.28CP.29_.26_Veliparib_777|CP & Veliparib]]
-| style="background-color:#d73027" |Inferior PFS
+| style="background-color:#d73027" |Inferior PFS (primary endpoint)<br><br>Did not meet secondary endpoint of OS<sup>1</sup>
 |-
 |}
+''<sup>1</sup>Reported efficacy is based on the 2024 update.''
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Confirmed deleterious germline BRCA1 or BRCA2 mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
 *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
 '''21-day cycles'''
+</div></div>
 ===References===
-#'''BROCADE3:''' Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269-1282. Epub 2020 Aug 27. [https://doi.org/10.1016/s1470-2045(20)30447-2 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32861273 PubMed] NCT02163694
+#'''BROCADE3:''' Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269-1282. Epub 2020 Aug 27. [https://doi.org/10.1016/s1470-2045(20)30447-2 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/32861273/ PubMed] [https://clinicaltrials.gov/study/NCT02163694 NCT02163694]
+##'''Update:''' Diéras V, Han HS, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Loirat D, Ratajczak C, Adamu H, Girardi V, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar;200:113580. Epub 2024 Jan 28. [https://doi.org/10.1016/j.ejca.2024.113580 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38309017/ PubMed]
 ==Docetaxel monotherapy {{#subobject:3e34a8|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:71bf06|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 161: / Line 179: @@
 |}
 ''<sup>1</sup>Reported efficacy is based on subgroup analysis.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
 '''21-day cycle for 6 to 8 cycles'''
+</div></div>
 ===References===
-# '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://www.nature.com/articles/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29713086 PubMed] NCT00532727
+# '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://doi.org/10.1038/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29713086/ PubMed] [https://clinicaltrials.gov/study/NCT00532727 NCT00532727]
 ==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:25ef0|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 180: / Line 197: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
-|2013-2017
+|2013-10 to 2017-04
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Talazoparib_monotherapy|Talazoparib]]
@@ Line 186: / Line 203: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
-|2014-2015
+|2014-04-07 to 2015-11-27
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Olaparib_monotherapy_2|Olaparib]]
@@ Line 192: / Line 209: @@
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *EMBRACA: Germline BRCA1 or BRCA2 mutation
 *OlympiAD: Confirmed deleterious or suspected deleterious germline BRCA mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] NCT02000622
+# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601/ PubMed] [https://clinicaltrials.gov/study/NCT02000622 NCT02000622]
-## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed]
+## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707/ PubMed]
-# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] NCT01945775
+# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579/ PubMed] [https://clinicaltrials.gov/study/NCT01945775 NCT01945775]
-## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825 PubMed]
+##'''PRO analysis:''' Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. [https://doi.org/10.1093/annonc/mdy257 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30124753/ PubMed]
+## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825/ PubMed]
 ==Gemcitabine monotherapy {{#subobject:af0915|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:11b425|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 217: / Line 236: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
-|2013-2017
+|2013-10 to 2017-04
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Talazoparib_monotherapy|Talazoparib]]
@@ Line 223: / Line 242: @@
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Germline BRCA1 or BRCA2 mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] NCT01945775
+# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579/ PubMed] [https://clinicaltrials.gov/study/NCT01945775 NCT01945775]
-## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825 PubMed]
+##'''PRO analysis:''' Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. [https://doi.org/10.1093/annonc/mdy257 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30124753/ PubMed]
+## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825/ PubMed]
 ==Olaparib monotherapy {{#subobject:a019cd|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 100 mg twice per day {{#subobject:31ed8c|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
 !style="width: 33%"|Study
-!style="width: 33%"|Years of enrollment
+!style="width: 33%"|Dates of enrollment
 !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
@@ Line 247: / Line 268: @@
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Olaparib (Lynparza)]] 100 mg PO twice per day
 '''Continued indefinitely'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 300 mg twice per day {{#subobject:3b0774|Variant=1}}===
 {| class="wikitable sortable" style="color:white; background-color:#404040"
@@ Line 259: / Line 281: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 265: / Line 287: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
-|2014-2015
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-166-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
+|-
+|} -->
+|2014-04-07 to 2015-11-27
 |style="background-color:#1a9851"|Phase 3 (E-RT-switch-ooc)
-|1. [[#Capecitabine_monotherapy|Capecitabine]]<br> 2. [[#Eribulin_monotherapy|Eribulin]]<br> 3. [[#Vinorelbine_monotherapy|Vinorelbine]]
+|Investigator's choice of:<br>1a. [[#Capecitabine_monotherapy|Capecitabine]]<br>1b. [[#Eribulin_monotherapy|Eribulin]]<br>1c. [[#Vinorelbine_monotherapy|Vinorelbine]]
-|style="background-color:#1a9850"|Superior PFS <br>Median PFS: 7.0 mo vs 4.2 mo <br>(HR 0.58, 95% CI 0.43-0.80)
+|style="background-color:#1a9850"|Superior PFS (primary endpoint)<br>Median PFS: 7.0 vs 4.2 mo <br>(HR 0.58, 95% CI 0.43-0.80)<br><br>Did not meet secondary endpoint of OS<sup>1</sup><br>Median OS: 19.3 vs 17.1 mo<br>(HR 0.90, 95% CI 0.66-1.23)
 |-
 |}
+''<sup>1</sup>Reported efficacy for OS is based on the 2019 update.''
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Confirmed deleterious or suspected deleterious germline BRCA mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Olaparib (Lynparza)]] 300 mg PO twice per day
 '''Continued indefinitely'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #3, 400 mg twice per day {{#subobject:31cf8c|Variant=1}}===
 {| class="wikitable sortable" style="width: 60%; text-align:center;"
 !style="width: 33%"|Study
-!style="width: 33%"|Years of enrollment
+!style="width: 33%"|Dates of enrollment
 !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
@@ Line 289: / Line 320: @@
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6057749/ Kaufman et al. 2014 (Study 42)]
-|2010-NR
+|2010-02-21 to 2012-07-31
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
-''Patients in Study 42 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.''
+<div class="toccolours" style="background-color:#fdcdac">
+====Biomarker eligibility criteria====
+*Study 42: Germline BRCA1/2 mutations
+====Prior treatment criteria====
+*Study 42: Progression after at least three lines of treatment for metastatic disease.
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Olaparib (Lynparza)]] 400 mg PO twice per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
-# '''KU36-44:''' Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. [https://doi.org/10.1016/S0140-6736(10)60892-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20609467 PubMed] NCT00494234
+# '''KU36-44:''' Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. [https://doi.org/10.1016/S0140-6736(10)60892-6 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20609467/ PubMed] [https://clinicaltrials.gov/study/NCT00494234 NCT00494234]
 <!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. -->
-# '''Study 42:''' Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [https://doi.org/10.1200/jco.2014.56.2728 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6057749/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25366685 PubMed] NCT01078662
+# '''Study 42:''' Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [https://doi.org/10.1200/jco.2014.56.2728 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6057749/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25366685/ PubMed] [https://clinicaltrials.gov/study/NCT01078662 NCT01078662]
-# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] NCT02000622
+# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601/ PubMed] [https://clinicaltrials.gov/study/NCT02000622 NCT02000622]
-## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed]
+## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707/ PubMed]
 ==Talazoparib monotherapy {{#subobject:bb55eb|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:06a5b4|Variant=1}}===
 {| class="wikitable" style="color:white; background-color:#404040"
@@ Line 315: / Line 351: @@
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
 !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1158/1078-0432.CCR-18-1891 Turner et al. 2018 (ABRAZO)]
+|2014-05 to 2016-02
+| style="background-color:#91cf61" |Phase 2
+| style="background-color:#d3d3d3" |
+| style="background-color:#d3d3d3" |
 |-
 |[https://doi.org/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
-|2013-2017
+<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"
+|'''[https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-165-1 <span style="color:white;">ESMO-MCBS (4)</span>]'''
+|-
+|} -->
+|2013-10 to 2017-04
 | style="background-color:#1a9851" |Phase 3 (E-RT-switch-ooc)
-|Physician's choice of:<br> 1. [[#Capecitabine_monotherapy|Capecitabine]]<br> 2. [[#Eribulin_monotherapy|Eribulin]]<br> 3. [[#Gemcitabine_monotherapy|Gemcitabine]]<br> 4. [[#Vinorelbine_monotherapy|Vinorelbine]]
+|Physician's choice of:<br>1a. [[#Capecitabine_monotherapy|Capecitabine]]<br>1b. [[#Eribulin_monotherapy|Eribulin]]<br>1c. [[#Gemcitabine_monotherapy|Gemcitabine]]<br>1d. [[#Vinorelbine_monotherapy|Vinorelbine]]
-| style="background-color:#1a9850" |Superior PFS<br>Median PFS: 8.6 vs 5.6 mo<br>(HR 0.54, 95% CI 0.41-0.71)
+| style="background-color:#1a9850" |Superior PFS (primary endpoint)<br>Median PFS: 8.6 vs 5.6 mo<br>(HR 0.54, 95% CI 0.41-0.71)<br><br>Did not meet secondary endpoint of OS<sup>1</sup><br>Median OS: 19.3 vs 19.5 mo<br>(HR 0.85, 95% CI 0.67-1.07)
 |-
 |}
+''<sup>1</sup>Reported efficacy for OS is based on the 2020 update.''
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Germline BRCA1 or BRCA2 mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Targeted therapy====
 *[[Talazoparib (Talzenna)]] 1 mg PO once per day
 '''Continued indefinitely'''
+</div></div>
 ===References===
-# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] NCT01945775
+# '''ABRAZO:''' Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 May 1;25(9):2717-2724. Epub 2018 Dec 18. [https://doi.org/10.1158/1078-0432.CCR-18-1891 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30563931/ PubMed] [https://clinicaltrials.gov/study/NCT02034916 NCT02034916]
-## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825 PubMed]
+# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30110579/ PubMed] [https://clinicaltrials.gov/study/NCT01945775 NCT01945775]
+##'''PRO analysis:''' Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. [https://doi.org/10.1093/annonc/mdy257 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30124753/ PubMed]
+## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825/ PubMed]
 ==Vinorelbine monotherapy {{#subobject:5c104c|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 2 out of 3 weeks {{#subobject:7321fd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 349: / Line 400: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
-|2014-2015
+|2014-04-07 to 2015-11-27
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Olaparib_monotherapy_2|Olaparib]]
@@ Line 355: / Line 406: @@
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Confirmed deleterious or suspected deleterious germline BRCA mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
 '''21-day cycles'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, weekly {{#subobject:bjab1fd|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
 !style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
+!style="width: 20%"|Dates of enrollment
 !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 !style="width: 20%"|Comparator
@@ Line 371: / Line 425: @@
 |-
 |[https://doi.org/10.1056/NEJMoa1802905 Litton et al. 2018 (EMBRACA)]
-|2013-2017
+|2013-10 to 2017-04
 | style="background-color:#1a9851" |Phase 3 (C)
 |[[#Talazoparib_monotherapy|Talazoparib]]
@@ Line 377: / Line 431: @@
 |-
 |}
+<div class="toccolours" style="background-color:#fdcdac">
 ====Biomarker eligibility criteria====
 *Germline BRCA1 or BRCA2 mutation
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV over 6 to 10 minutes once per day on days 1, 8, 15
 '''21-day cycles'''
+</div></div>
 ===References===
-# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] NCT02000622
+# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://doi.org/10.1056/NEJMoa1706450 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/28578601/ PubMed] [https://clinicaltrials.gov/study/NCT02000622 NCT02000622]
-## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed]
+## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707/ PubMed]
-# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] NCT01945775
+# '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://doi.org/10.1056/NEJMoa1802905 link to original article] '''contains dosing details in supplement''' [https://pubmed.ncbi.nlm.nih.gov/30110579/ PubMed] [https://clinicaltrials.gov/study/NCT01945775 NCT01945775]
-## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825 PubMed]
+##'''PRO analysis:''' Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. [https://doi.org/10.1093/annonc/mdy257 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30124753/ PubMed]
+## '''Update:''' Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov;31(11):1526-1535. Epub 2020 Aug 20. [https://doi.org/10.1016/j.annonc.2020.08.2098 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32828825/ PubMed]
 =Additional resources=
 *[[Breast cancer BRCA1 & BRCA2 genetic testing]]
 *[https://oncomx.org/searchview/?gene=BRCA1 OncoMX -- BRCA1]
 *[https://oncomx.org/searchview/?gene=BRCA2 OncoMX -- BRCA2]
 [[Category:Breast cancer regimens]]
 [[Category:Biomarker-specific pages]]
 [[Category:Malignant breast neoplasm]]

Difference between revisions of "Breast cancer, BRCA-mutated"

Latest revision as of 17:45, 23 June 2024

Guidelines

ASCO

ESMO

NCCN

Adjuvant therapy

Olaparib monotherapy

Regimen

Preceding treatment

Targeted therapy

References

Advanced or metastatic disease, subsequent lines of therapy

Capecitabine monotherapy

Regimen

Biomarker eligibility criteria

Chemotherapy

References

Carboplatin monotherapy

Regimen

Chemotherapy

References

Carboplatin & Paclitaxel (CP)

Regimen

Biomarker eligibility criteria

Chemotherapy

References

Docetaxel monotherapy

Regimen

Chemotherapy

References

Eribulin monotherapy

Regimen

Biomarker eligibility criteria

Chemotherapy

References

Gemcitabine monotherapy

Regimen

Biomarker eligibility criteria

Chemotherapy

References

Olaparib monotherapy

Regimen variant #1, 100 mg twice per day

Targeted therapy

Regimen variant #2, 300 mg twice per day

Biomarker eligibility criteria

Targeted therapy

Regimen variant #3, 400 mg twice per day

Biomarker eligibility criteria

Prior treatment criteria

Targeted therapy

References

Talazoparib monotherapy

Regimen

Biomarker eligibility criteria

Targeted therapy

References

Vinorelbine monotherapy

Regimen variant #1, 2 out of 3 weeks

Biomarker eligibility criteria

Chemotherapy

Regimen variant #2, weekly

Biomarker eligibility criteria

Chemotherapy

References

Additional resources

Navigation menu

Search